Search all medical codes

Injection, ado-trastuzumab emtansine, 1 mg

HCPCS code

Name of the Procedure:

Injection, ado-trastuzumab emtansine, 1 mg Common names: Kadcyla Injection, T-DM1 Injection Medical term: Injection, ado-trastuzumab emtansine, 1 mg (HCPCS Code J9354)

Summary

The injection of ado-trastuzumab emtansine (Kadcyla) is a treatment used mainly for specific types of breast cancer. It combines the targeting mechanisms of a monoclonal antibody (trastuzumab) with the anti-cancer chemotherapy drug emtansine, aiming to kill cancer cells while minimizing damage to healthy cells.

Purpose

Conditions Addressed:
  • HER2-positive metastatic breast cancer
  • Breast cancer that has spread and does not respond to other HER2 therapies
Goals:
  • Shrink cancer tumors
  • Inhibit cancer growth
  • Prolong patient survival
  • Improve quality of life

Indications

Symptoms/Conditions:
  • Diagnosed HER2-positive breast cancer
  • Metastatic cancer
  • Cancer unresponsive to previous HER2-targeted therapies
Patient Criteria:
  • HER2-positive status confirmed via specific tests (e.g., IHC and/or FISH tests)
  • Prior treatment regimes failed, including trastuzumab and taxane therapies

Preparation

Pre-Procedure Instructions:
  • No special dietary restrictions typically required
  • Review current medications with healthcare provider; some may need to be adjusted
  • Blood tests to check white blood cell count, liver function, and overall health
Required Assessments:
  • Cardiac function test (ECHO or MUGA scan)
  • Confirmatory biopsy to verify HER2-positive cancer

Procedure Description

Steps:
  1. Patient sits in a comfortable chair or lies on an exam bed.
  2. An intravenous (IV) line is inserted into a vein.
  3. Ado-trastuzumab emtansine (Kadcyla) is infused through the IV over approximately 30-90 minutes.
  4. Patient is monitored for any immediate reactions.
Tools/Equipment:
  • Sterile IV line and infusion pump
  • Kadcyla medication
  • Monitoring equipment (heart rate, blood pressure, etc.)
Anesthesia/Sedation:
  • Generally, none required as it is an IV infusion

Duration

Typical infusion lasts 30-90 minutes. The procedure may be repeated every three weeks, depending on the treatment plan.

Setting

Performed in a hospital outpatient clinic, cancer center, or specialized infusion center.

Personnel

  • Oncologist or specialized oncology nurse to administer the infusion
  • Nurse for patient monitoring and support
  • Pharmacist for medication preparation

Risks and Complications

Common Risks:
  • Nausea
  • Fatigue
  • Headache
  • Fever
  • Low platelet counts

    Rare Risks:
  • Severe allergic reactions
  • Heart problems (congestive heart failure)
  • Liver toxicity
Management:
  • Pre-medication with anti-nausea drugs
  • Regular monitoring of heart and liver function
  • Immediate medical intervention for allergic reactions

Benefits

Expected Outcomes:
  • Tumor size reduction and slowed cancer progression
  • Prolongation of life expectancy in metastatic breast cancer patients
  • Improved quality of life and symptomatic relief
Timeline for Benefits:
  • Positive outcomes may be observed within months of consistent treatment

Recovery

Post-Procedure Care:
  • Patients can usually go home the same day
  • Activity levels can often be maintained
  • Monitoring for side effects like low blood cell counts and liver function may be required
Recovery Time:
  • No significant downtime, but regular follow-ups every three weeks for continued treatment
Restrictions/Follow-Up:
  • Avoid exposure to infections due to lowered immunity
  • Regular follow-up appointments for blood tests and heart assessments

Alternatives

Other Options:
  • Other HER2-targeted therapies (e.g., trastuzumab, pertuzumab)
  • Chemotherapy
  • Hormonal therapy
Pros and Cons:
  • Alternatives may be useful for different patient profiles or stages of treatment
  • Kadcyla is often preferred for its double-targeting mechanism, though specific patient conditions will dictate suitability

Patient Experience

During the Procedure:
  • Minor discomfort from IV insertion
  • Sitting or lying relaxed for an hour or more
After the Procedure:
  • Potential mild side effects: fatigue, mild nausea
  • Pain management includes over-the-counter remedies for headaches or discomfort
  • Supportive care strategies (hydration, rest) recommended

Medical Policies and Guidelines for Injection, ado-trastuzumab emtansine, 1 mg

Related policies from health plans

Kadcyla (ado-trastuzumab)

Similar Codes